Study demonstrates new mechanism of action for imatinib
This article has no abstract so we have provided the first paragraph of the full text.
Imatinib is a tyrosine kinase inhibitor widely used in the treatment of chronic myelogenous leukemia. Originally designed to target the chronic-myelogenous-leukemia-specific tyrosine kinase bcr–abl, imatinib has since been shown to inhibit a number of important tyrosine kinases involved in cell growth and survival. Now, Ertmer et al. have demonstrated a further mechanism through which imatinib might induce growth arrest in cancer cells.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Mycobacterial virulence and specialized secretion: same story, different endingNature Medicine News and Views (01 Mar 2007)